Plasmodium falciparum malaria
ICD-10 B53.1 is a billable code used to indicate a diagnosis of plasmodium falciparum malaria.
Plasmodium falciparum malaria is a severe form of malaria caused by the Plasmodium falciparum parasite, which is transmitted to humans through the bite of infected Anopheles mosquitoes. This species is responsible for the majority of malaria-related morbidity and mortality worldwide. Clinical manifestations can range from mild flu-like symptoms to severe complications such as cerebral malaria, acute respiratory distress syndrome, and multi-organ failure. Diagnosis is typically confirmed through blood smears or rapid diagnostic tests that identify the presence of the parasite. Treatment involves the use of antimalarial medications, with artemisinin-based combination therapies (ACTs) being the first-line treatment. However, resistance to antimalarial drugs, particularly in certain regions, poses a significant challenge in managing the disease. Prophylaxis is recommended for travelers to endemic areas, utilizing medications such as atovaquone-proguanil, doxycycline, or mefloquine, depending on the region and individual patient factors. Understanding the epidemiology, clinical presentation, and treatment options for Plasmodium falciparum malaria is crucial for effective management and coding.
Detailed patient history, including travel and exposure risks, laboratory results confirming diagnosis, and treatment plans.
Patients presenting with fever and travel history to endemic areas, severe malaria cases requiring hospitalization.
Ensure documentation reflects the severity of the disease and any complications for accurate coding.
Patient travel history, prophylaxis recommendations, and any post-travel symptoms.
Pre-travel consultations for malaria prophylaxis, post-travel evaluations for symptomatic patients.
Documenting the specific regions visited and adherence to prophylaxis guidelines is crucial.
Used in conjunction with B53.1 for diagnosis confirmation.
Document the reason for the test and results.
Infectious disease specialists should ensure accurate interpretation of test results.
The primary treatment for Plasmodium falciparum malaria is artemisinin-based combination therapy (ACT), which is effective against this species and helps reduce the risk of resistance.
